Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: a systematic review and meta-analysis
8.5
来源：
Nature
发布时间：
2025-08-27 03:43
摘要：
MRI-based risk calculators significantly enhance the diagnostic accuracy for clinically significant prostate cancer (csPCa), outperforming traditional clinical models. This systematic review and meta-analysis, which included 16 studies from diverse regions, demonstrated that MRI-based calculators achieved a pooled AUC of 0.84 for csPCa, indicating improved discrimination. The integration of MRI findings with clinical variables not only reduces unnecessary biopsies but also optimizes healthcare resources, supporting better patient outcomes. The findings underscore the potential of MRI-based risk calculators in transforming prostate cancer diagnostics.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
MRI-based RCs showed increased discrimination, with an AUC of 0.84 for clinically significant PCa.
The pooled logit(AUC) difference was 0.49 units for csPCa, indicating enhanced ability to discriminate.
MRI-based RCs integrate imaging findings with clinical variables, improving risk estimation.
真实性检查
否
AI评分总结
MRI-based risk calculators significantly enhance the diagnostic accuracy for clinically significant prostate cancer (csPCa), outperforming traditional clinical models. This systematic review and meta-analysis, which included 16 studies from diverse regions, demonstrated that MRI-based calculators achieved a pooled AUC of 0.84 for csPCa, indicating improved discrimination. The integration of MRI findings with clinical variables not only reduces unnecessary biopsies but also optimizes healthcare resources, supporting better patient outcomes. The findings underscore the potential of MRI-based risk calculators in transforming prostate cancer diagnostics.